Which has higher earnings & valuation, CGEM or ELTX?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A

Is CGEM or ELTX more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Elicio Therapeutics N/A -2,748.16% -151.12%

Is ABSI or ELTX more profitable?

Elicio Therapeutics has a net margin of 0.00% compared to Absci's net margin of -6,450.76%. Absci's return on equity of -66.32% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Absci -6,450.76% -66.32% -57.01% Elicio Therapeutics N/A -2,748.16% -151.12%

Which has stronger earnings and valuation, ELTX or OLMA?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is ELTX or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% Olema Pharmaceuticals N/A -46.00% -41.22%

Which has higher earnings and valuation, ELTX or ANNX?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is ELTX or ANNX more profitable?

Annexon's return on equity of -101.19% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% Annexon N/A -101.19% -75.99%

Elicio Therapeutics (ELTX) Competitors

$14.85 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$14.64 -0.22 (-1.45%)

As of 06/12/2026 06:57 PM Eastern

Compare

ELTX vs. ALVO, CGEM, ABSI, OLMA, and ANNX

Should you buy Elicio Therapeutics stock or one of its competitors? MarketBeat compares Elicio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elicio Therapeutics include Alvotech (ALVO), Cullinan Therapeutics (CGEM), Absci (ABSI), Olema Pharmaceuticals (OLMA), and Annexon (ANNX). These companies are all part of the "med - biomed/gene" industry.

How does Elicio Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Alvotech has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Alvotech has higher revenue and earnings than Elicio Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	2.14	$27.92M	-$0.25	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

In the previous week, Alvotech had 10 more articles in the media than Elicio Therapeutics. MarketBeat recorded 12 mentions for Alvotech and 2 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.44 beat Alvotech's score of 0.76 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alvotech	Positive
Elicio Therapeutics	Positive

Alvotech currently has a consensus target price of $7.60, indicating a potential upside of 82.25%. Elicio Therapeutics has a consensus target price of $20.25, indicating a potential upside of 36.36%. Given Alvotech's higher probable upside, research analysts clearly believe Alvotech is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Elicio Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

35.0% of Elicio Therapeutics shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Elicio Therapeutics beats Alvotech on 9 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Elicio Therapeutics. MarketBeat recorded 10 mentions for Cullinan Therapeutics and 2 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.44 beat Cullinan Therapeutics' score of 0.53 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cullinan Therapeutics	Positive
Elicio Therapeutics	Positive

Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 133.58%. Elicio Therapeutics has a consensus target price of $20.25, suggesting a potential upside of 36.36%. Given Cullinan Therapeutics' higher possible upside, equities analysts clearly believe Cullinan Therapeutics is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Cullinan Therapeutics' return on equity of -51.45% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

Summary

Cullinan Therapeutics and Elicio Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Elicio Therapeutics has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	378.61	-$115.18M	-$0.83	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

52.1% of Absci shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Absci had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 5 mentions for Absci and 2 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.44 beat Absci's score of 0.55 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Absci	Positive
Elicio Therapeutics	Positive

Absci presently has a consensus target price of $8.52, indicating a potential upside of 25.25%. Elicio Therapeutics has a consensus target price of $20.25, indicating a potential upside of 36.36%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Absci has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Elicio Therapeutics has a net margin of 0.00% compared to Absci's net margin of -6,450.76%. Absci's return on equity of -66.32% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-6,450.76%	-66.32%	-57.01%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Summary

Absci and Elicio Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to Olema Pharmaceuticals?

Elicio Therapeutics (NASDAQ:ELTX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Olema Pharmaceuticals' return on equity of -46.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Elicio Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Elicio Therapeutics currently has a consensus price target of $20.25, suggesting a potential upside of 36.36%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 346.81%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Olema Pharmaceuticals had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 2 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.44 beat Olema Pharmaceuticals' score of 0.38 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Positive
Olema Pharmaceuticals	Neutral

Summary

Olema Pharmaceuticals beats Elicio Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Annexon?

Elicio Therapeutics (NASDAQ:ELTX) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Annexon's return on equity of -101.19% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Annexon	N/A	-101.19%	-75.99%

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Elicio Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Elicio Therapeutics currently has a consensus target price of $20.25, suggesting a potential upside of 36.36%. Annexon has a consensus target price of $16.00, suggesting a potential upside of 239.70%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Annexon had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 5 mentions for Annexon and 2 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.44 beat Annexon's score of 0.97 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Positive
Annexon	Positive

35.0% of Elicio Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 10.3% of Annexon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Annexon beats Elicio Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELTX vs. The Competition

Export

Metric	Elicio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$283.43M	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-6.19	20.00	23.99	24.42
Price / Sales	N/A	305.33	511.38	110.47
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	165.00	8.32	10.65	6.82
Net Income	-$39.57M	$23.94M	$3.57B	$337.56M
7 Day Performance	9.59%	1.84%	0.58%	1.17%
1 Month Performance	39.70%	-0.04%	1.54%	3.16%
1 Year Performance	95.39%	44.82%	25.40%	30.58%

Elicio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELTX Elicio Therapeutics	2.3691 of 5 stars	$14.85 flat	$20.25 +36.4%	+95.4%	$283.43M	N/A	N/A	N/A	Positive News Gap Down
ALVO Alvotech	3.95 of 5 stars	$3.74 +19.1%	$7.60 +103.2%	-57.2%	$947.67M	$588.90M	N/A	1,460	Gap Up High Trading Volume
CGEM Cullinan Therapeutics	3.6302 of 5 stars	$14.43 -5.1%	$30.75 +113.1%	+59.1%	$934.78M	N/A	N/A	30	Analyst Upgrade
ABSI Absci	3.3044 of 5 stars	$7.34 +23.6%	$8.52 +16.0%	+144.6%	$926.08M	$2.80M	N/A	210	High Trading Volume
OLMA Olema Pharmaceuticals	2.4957 of 5 stars	$10.68 +1.6%	$44.10 +312.9%	+136.7%	$918.02M	N/A	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elicio Therapeutics (ELTX) Competitors

ELTX vs. ALVO, CGEM, ABSI, OLMA, and ANNX

How does Elicio Therapeutics compare to Alvotech?

Summary

How does Elicio Therapeutics compare to Cullinan Therapeutics?

Summary

How does Elicio Therapeutics compare to Absci?

Summary

How does Elicio Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Elicio Therapeutics compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elicio Therapeutics (ELTX) Competitors

ELTX vs. ALVO, CGEM, ABSI, OLMA, and ANNX

How does Elicio Therapeutics compare to Alvotech?

Which has more risk and volatility, ALVO or ELTX?

Which has preferable valuation and earnings, ALVO or ELTX?

Does the media prefer ALVO or ELTX?

Do analysts rate ALVO or ELTX?

Is ALVO or ELTX more profitable?

Do insiders and institutionals have more ownership in ALVO or ELTX?

Summary

How does Elicio Therapeutics compare to Cullinan Therapeutics?

Do institutionals and insiders hold more shares of CGEM or ELTX?

Does the media favor CGEM or ELTX?

Which has more volatility and risk, CGEM or ELTX?

Do analysts recommend CGEM or ELTX?

Is CGEM or ELTX more profitable?

Which has higher earnings & valuation, CGEM or ELTX?

Summary

How does Elicio Therapeutics compare to Absci?

Which has preferable valuation & earnings, ABSI or ELTX?

Do insiders & institutionals believe in ABSI or ELTX?

Does the media prefer ABSI or ELTX?

Do analysts rate ABSI or ELTX?

Which has more volatility and risk, ABSI or ELTX?

Is ABSI or ELTX more profitable?

Summary

How does Elicio Therapeutics compare to Olema Pharmaceuticals?

Is ELTX or OLMA more profitable?

Do institutionals and insiders hold more shares of ELTX or OLMA?

Which has stronger earnings and valuation, ELTX or OLMA?

Which has more risk and volatility, ELTX or OLMA?

Do analysts prefer ELTX or OLMA?

Does the media refer more to ELTX or OLMA?

Summary

How does Elicio Therapeutics compare to Annexon?

Is ELTX or ANNX more profitable?

Which has higher earnings and valuation, ELTX or ANNX?

Which has more risk and volatility, ELTX or ANNX?

Do analysts prefer ELTX or ANNX?

Does the media favor ELTX or ANNX?

Do institutionals and insiders believe in ELTX or ANNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools